EW
HealthcareEdwards Lifesciences Corporation · Medical - Devices · $49B
What is Edwards Lifesciences Corporation?
Edwards Lifesciences Corporation is a global medical technology company focused on structural heart disease and critical care monitoring. Headquartered in Irvine, California, it serves patients and clinicians across the United States, Europe, Japan, and beyond.
The company develops and commercializes technologies that treat diseased or damaged heart valves through both minimally invasive and surgical approaches. Its transcatheter systems allow physicians to repair or replace heart valves without open-heart surgery, while its surgical solutions address more complex structural conditions. Edwards also provides critical care monitoring tools that help clinicians track heart function and fluid status in intensive care and surgical environments, supporting better patient outcomes at the point of care.
Edwards Lifesciences was founded in 1958 and is headquartered in Irvine, California.
- Transcatheter heart valve replacement systems for minimally invasive procedures
- PASCAL and Cardioband valve repair systems for mitral and tricuspid disease
- INSPIRIS aortic surgical valve and KONECT RESILIA valved conduit
- HARPOON Beating Heart Mitral Valve Repair System
- Acumen Hypotension Prediction Index critical care monitoring software
Is EW a Good Stock to Buy?
UQS Score rates EW as Good overall, reflecting a balanced profile across its five analytical pillars.
The Risk pillar stands out as the clearest strength, suggesting Edwards carries a relatively conservative financial and operational risk profile compared to many healthcare peers. The Quality pillar also registers as Good, pointing to a business that generates consistent returns and maintains sound fundamentals.
The Moat and Growth pillars both register as Neutral, indicating that competitive differentiation and near-term expansion momentum are not yet standout features relative to the broader sector.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does EW pay dividends?
No — Edwards Lifesciences Corporation does not currently pay a dividend.
Edwards Lifesciences does not currently pay a dividend. For a company operating at the intersection of medical innovation and clinical care, this is consistent with a reinvestment-focused strategy — directing capital toward research, product development, and expanding its structural heart and critical care platforms rather than distributing cash to shareholders.
When does EW report earnings?
Edwards Lifesciences reports earnings on a quarterly cadence, consistent with standard practice for US-listed large-cap equities.
The company's Quality pillar rating suggests its financial results have been broadly consistent, though the Neutral Growth rating indicates the pace of expansion has been measured rather than accelerating. Investors tracking quarterly results should watch commentary on transcatheter valve adoption and critical care segment trends.
For the most recent quarter's results and guidance, visit Edwards Lifesciences' investor relations page directly.
EW Price History
-16.9% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Edwards Lifesciences Corporation?
Based on Edwards Lifesciences Corporation's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
EW Long-term Outlook
Edwards Lifesciences' fundamental outlook is shaped by its Neutral Growth and Strong Risk pillar profile. The combination suggests a company that prioritizes financial stability over aggressive top-line expansion — a posture that may appeal to investors seeking durability in healthcare. The structural heart disease market continues to grow as aging populations drive demand for valve therapies, but competitive intensity and reimbursement dynamics remain variables to monitor.
Growth drivers
- Aging global population increasing demand for structural heart valve therapies
- Ongoing adoption of minimally invasive transcatheter procedures over open surgery
- Expansion of critical care monitoring into new hospital settings internationally
Key risks
- Competitive pressure from established medtech players in the structural heart space
- Reimbursement and regulatory approval timelines for new product indications
- Valuation at a Neutral level leaves limited margin of safety if growth disappoints
EW vs Peers
Edwards Lifesciences competes across structural heart and critical care monitoring with several large medtech and diagnostics companies.
Philips operates across a broader imaging and patient monitoring portfolio, competing with Edwards primarily in hospital-based critical care technology rather than structural heart therapies.
DexCom focuses on continuous glucose monitoring for diabetes management, representing a different segment of patient monitoring technology with less direct overlap in cardiac care.
Boston Scientific competes more directly in structural heart and interventional cardiology, offering a broad device portfolio that overlaps with Edwards' transcatheter valve franchise.
Frequently Asked Questions
What does Edwards Lifesciences do?
Edwards Lifesciences develops medical technologies for structural heart disease and critical care monitoring. Its core products include transcatheter heart valve replacement and repair systems, surgical valve solutions, and hemodynamic monitoring tools used in intensive care and surgical settings worldwide.
Does EW pay dividends?
Edwards Lifesciences does not currently pay a dividend. The company reinvests its capital into research, product development, and expanding its structural heart and critical care platforms rather than returning cash to shareholders through regular distributions.
When does EW report earnings?
Edwards Lifesciences follows a standard quarterly earnings cadence for US-listed companies. For the most current reporting schedule and recent results, check the investor relations section of the Edwards Lifesciences website directly.
Is EW a good stock to buy?
UQS Score rates EW as Good overall. Its Risk pillar is Strong and Quality registers as Good, while Moat and Growth are Neutral. Whether it fits your portfolio depends on your investment goals — the full pillar breakdown is available to UQS Pro members.
Is EW overvalued?
EW's Valuation pillar registers as Neutral, suggesting the market is pricing the stock in line with its fundamentals rather than at a significant premium or discount. Investors seeking a margin of safety may want to review the detailed valuation metrics available in the full UQS analysis.
How does EW compare to its competitors?
Among peers like Boston Scientific, Philips, and DexCom, Edwards Lifesciences is more narrowly focused on structural heart disease and cardiac monitoring. This specialization can be a strength in clinical depth but may limit diversification compared to broader medtech platforms.
What is EW's market cap bracket?
Edwards Lifesciences is classified as a large-cap company, placing it among the more established and widely followed names in the healthcare and medical device sector.
Who founded Edwards Lifesciences?
Edwards Lifesciences traces its origins to Miles Edwards, a pioneer in heart valve technology. The company has roots going back to 1958 and has since grown into a global leader in structural heart therapies and critical care monitoring.
Is EW a long-term quality investment?
From a quality indicator standpoint, EW's Strong Risk pillar and Good Quality pillar suggest a business with durable fundamentals. Long-term suitability depends on how the Growth and Moat pillars evolve — factors that UQS Pro members can track through the full scoring breakdown.
What is the main competitive advantage of Edwards Lifesciences?
Edwards has built deep clinical expertise in transcatheter heart valve therapies, a specialized and technically demanding field. Its established relationships with cardiac surgeons and interventional cardiologists, combined with a focused product portfolio, support its position in structural heart care.
What sector does EW belong to?
Edwards Lifesciences operates in the Healthcare sector, specifically within the medical devices and technology segment. It focuses on structural heart disease treatment and critical care patient monitoring, areas that sit at the intersection of cardiology and hospital-based care.
Is EW a growth stock or value stock?
Based on its UQS profile, EW sits in a middle ground — its Growth pillar is Neutral and its Valuation pillar is also Neutral. It does not fit neatly into either a high-growth or deep-value category, making it more of a quality-oriented holding for investors focused on stability.
Unlock Full EW Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar ratings
- ✓Access detailed financial metrics and trend data
- ✓Compare EW against peers on a standardized scoring framework
- ✓Track Quality, Moat, Growth, Risk, and Valuation over time
- ✓Get the complete analyst-grade view reserved for Pro members
Pro Analysis
EW — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 11, 2026 | 59.3 | 64.4 | 53.0 | 50.2 | 82.4 | 50.7 | 0.0 |
| May 7, 2026 | 59.3 | 65.0 | 53.0 | 50.2 | 82.4 | 49.2 | +0.1 |
| May 6, 2026 | 59.2 | 65.0 | 53.0 | 50.2 | 82.4 | 49.0 | 0.0 |
| May 3, 2026 | 59.2 | 65.0 | 53.0 | 50.1 | 82.4 | 49.0 | 0.0 |
| Apr 26, 2026 | 59.2 | 65.0 | 53.0 | 50.1 | 82.4 | 48.9 | 0.0 |
| Apr 25, 2026 | 59.2 | 65.0 | 53.0 | 49.3 | 82.4 | 49.8 | +0.2 |
| Apr 19, 2026 | 59.0 | 64.5 | 53.0 | 48.8 | 82.4 | 49.8 | -0.1 |
| Apr 18, 2026 | 59.1 | 64.5 | 53.0 | 48.9 | 82.4 | 51.0 | -2.0 |
| Apr 17, 2026 | 61.1 | 64.6 | 53.0 | 48.9 | 82.4 | 63.7 | 0.0 |
| Apr 12, 2026 | 61.1 | 64.7 | 53.0 | 48.9 | 82.4 | 63.7 | +0.2 |
EW — Pillar Breakdown
Quality
— 64.1/100 (25%)Edwards Lifesciences Corporation shows solid profitability with healthy returns on capital and reasonable margins.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 50.2/100 (20%)Edwards Lifesciences Corporation shows steady but unspectacular growth, typical for mature companies.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 82.4/100 (15%)Edwards Lifesciences Corporation carries minimal financial risk with conservative leverage and strong solvency.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 48.4/100 (15%)Edwards Lifesciences Corporation has a mixed valuation — some metrics suggest fair value while others appear stretched.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 53/100 (25%)Edwards Lifesciences Corporation possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for EW.
Score Composition
Financial Data
More Stock Analysis
How is the EW UQS Score Calculated?
The UQS (Unified Quality Score) for Edwards Lifesciences Corporation is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Edwards Lifesciences Corporation's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Edwards Lifesciences Corporation is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.